SAN DIEGO, April 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced the establishment of a Named Patient Program for SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System. A Named Patient Program is a mechanism through which physicians can legally and ethically prescribe drugs which are investigational or not yet approved in a specific country.
